Pharmacia parecoxib
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Injectable COX-2 inhibitor for management of acute pain is deemed "not approvable" by FDA July 13. The company says it plans to respond to the letter within 12 to 18 months